Medifast (NYSE:MED) Issues Q4 2024 Earnings Guidance

Medifast (NYSE:MED) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.100-0.650 for the period, compared to the consensus estimate of -0.180. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.0 million.

Analyst Ratings Changes

Separately, DA Davidson restated an “underperform” rating and set a $17.50 target price on shares of Medifast in a research note on Monday, July 22nd.

Medifast Stock Performance

NYSE MED traded up $0.23 during trading hours on Monday, reaching $18.81. The stock had a trading volume of 205,795 shares, compared to its average volume of 390,565. The stock has a market cap of $205.72 million, a P/E ratio of 7.02 and a beta of 1.13. Medifast has a 52-week low of $17.07 and a 52-week high of $76.42. The stock has a fifty day moving average of $18.43 and a 200 day moving average of $21.00.

Medifast (NYSE:MED) last issued its quarterly earnings data on Monday, August 5th. The specialty retailer reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.56. Medifast had a net margin of 3.81% and a return on equity of 25.77%. The firm had revenue of $168.56 million for the quarter, compared to analyst estimates of $160.44 million. During the same period in the previous year, the firm earned $2.77 EPS. On average, equities research analysts forecast that Medifast will post 1.12 EPS for the current year.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.